Skip to main content
. 2020 Apr 16;21:89. doi: 10.1186/s12931-020-01356-6

Table 3.

Clinical characteristics and sputum cell numbers in asthma inflammatory phenotypes

Variable EA NA MA PA P value
Number 38 4 9 38
Age (years) 47.08 ± 13.54△ ※ 64.25 ± 6.75 56.22 ± 11.92§ 55.18 ± 12.18§ 0.007
Male (%) 15 (39.5) 1 (25.0) 4 (44.4) 17 (44.7) 0.899
BMI (kg/m2) 23.97 ± 3.20 22.44 ± 3.02 25.77 ± 3.74 23.44 ± 3.70 0.271
ACQ† [21] 2.0 (2.0, 3.0) 1.5 (1.0, 2.0) 2.0 (0.3, 2.8) 2.0 (1.0, 2.0) 0.930
ACT† [22] 15 (12, 18) 17.5 (5.5, 19.0) 18 (12, 22.5) 17 (13, 21.75) 0.222
AQLQ† [23] 4 (4, 5) 5 (5, 5) 5 (5, 7) 5 (4, 5) 0.409
Rhinitis (%)† 13 (37.1) 1 (25) 4 (44.4) 17 (44.7) 0.208
Anxiety† [24] 5 (0, 7) 2 (0, 5) 0 (0, 11) 4 (0, 6) 0.473
Depression† [25] 3 (0, 7) 3 (0, 7) 0 (0, 7) 1 (0, 5) 0.771
Ex-smoker (%)† 16 (43.2) 3 (75.0) 6 (66.7) 13 (34.2) 0.154
Smoking index† 0 (0, 6.9) 12.4 (2.4, 33.8) 1.0 (0.0, 32.5) 0.0 (0.0, 19.5) 0.323
Post-bronchodilator FEV1 (L) † 2.33 (2.08, 3.13) 0.67 (0.67, 1.61) 2.27 (1.64, 2.92) 2.42 (1.38, 3.04) 0.538
Post-bronchodilatorFEV1/pred (%)† 87 (70.8, 97.7) 29.3 (27.65, 68.9) 81.4 (57.6, 99.15) 90.8 (54.1, 100.4) 0.634
Post-bronchodilator FVC (L) † 3.74 (3.11, 4.48) 1.9 (1.71, 2.61) 3.44 (3.07, 3.78) 3.67 (2.39, 4.18) 0.892
Post-bronchodilator FVC/pred (%)† 106.67 ± 24.46 73.33 ± 36.35 94.2 ± 24.95 100.59 ± 26.84 0.633
FeNO (ppd) † 42.4 (32.65, 131.5) 23 (18, 76) 72.4 (38, 108.2) 37 (22.7, 47.45) § 0.195
ICS/LABA, n (%)† 37 (97.3) 4 (100) 9 (100) 28 (73.7) 0.239
ICS dose (μg)† 400 (400, 500) 450 (400, 500) 400 (325, 500) 500 (400, 800) 0.319
Sputum Cell Count (median (q1,q3))
 Total cells(106/mL) † 3.6 (1.8, 5.4) 3.0 (0.75, 7.55) 2.9 (1.8, 3.6) 2.9 (1.8, 5.4) 0.812
 Neutrophils (106/mL) † 0.07 (0.01, 1.38) #※ 2 (0.61, 4.59) △§ 1.83 (1.32, 2.65) △§ 0.06 (0.01, 0.48) #※ <0.001
 Neutrophils, %, † 4.0 (1.2, 10.0) #※ 65.25 (61.0, 82.4) △§ 70(63.3, 73.4) △§ 2.2 (0.6, 24.0) #※ <0.001
 Eosinophils (106/mL) † 0.82 (0.21, 1.37) #※△ 0.01 (0, 0.13) § 0.12 (0.09, 0.22) § 0 (0, 0.04) § <0.001
 Eosinophils, %, † 17.0 (8.7, 40.1) #※△ 1.6 (0.2, 2.8) § 4.9 (3.3, 13.1) § 0.2 (0, 1.0) § <0.001
 Macrophages (106/mL) † 1.55 (0.31, 3.51) #※△ 0.56 (0.01, 1.16) §※ 0.47 (0.11, 0.77) §※ 1.91 (0.56, 4.52) § #※ <0.001
 Macrophages, %, † 58.3 (37.3, 80.5) #※△ 15.1 (7.8, 24.8)§※ 21.3 (11.4, 28.0) §※ 85.4 (49.1, 95.6) § #※ <0.001
 Lymphocytes (106/mL) † 0.03 (0, 0.15) 0.21 (0.01, 0.66) 0 (0, 0.01) 0.03 (0, 0.17) 0.406
 Lymphocytes, %, † 1.8 (0.5, 6.6) 5.9 (2.9, 8.9) 0 (0, 0.5) 1.4 (0.3, 13.0) 0.562
 Columnar epithelial cells (106/mL) † 0.04(0, 1.09) 0.1 (0.02, 1.42) 0 (0, 11.79) 0.05 (0.01, 0.24) 0.072
 Columnar epithelial cells, %, † 1.4(0.5, 3.0) 3.8 (2.8, 14.7) 0 (0, 2.6) 3. 5 (0.8, 11.4) §※ 0.017

Note: Data are expressed as mean ± SD or median (IQR). Data were analyzed using an ANOVA or Kruskal-Wallis test. †: adjusted for age. NA neutrophil type, MA mixed granulocyte type, PA granulocyte-deficient type, EA eosinophilic type. p < 0.05: # vs.NA, vs. MA, vs. PA, § vs. EA. BMI Body mass index, ACT asthma control test, ACQ Asthma control questionnaire, AQLQ-S Asthma Quality of Life Questionnaire, FeNO Fractional exhaled nitric oxide, FVC Forced vital capacity, FEV1 Forced expiratory volume in 1 s, ICS Inhaled corticosteroid, LABA long-acting β2-agonists